Does Dr. TASOS ASLANIDIS have financial conflicts of interest?

Dr. TASOS ASLANIDIS (D.O.) has received a total of $648 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $648 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. TASOS ASLANIDIS?

According to CMS Open Payments data, Dr. TASOS ASLANIDIS received funding from REGENERON HEALTHCARE SOLUTIONS ($242), INTEGRA LIFESCIENCES CORPORATION ($173), and GENZYME CORPORATION ($104).

Does Dr. TASOS ASLANIDIS receive research grants or speaking fees?

Dr. TASOS ASLANIDIS has received $648 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. TASOS ASLANIDIS

D.O.Real-Time Hydrated

Specialty: Otolaryngology, Otolaryngology/Facial Plastic Surgery

Practice Location: PHILADELPHIA, PA 19148

NPI Number: 1568438703

LIFETIME INDUSTRY VALUE

$648

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ASLANIDIS is a verified Otolaryngology, Otolaryngology/Facial Plastic Surgery practitioner based in PHILADELPHIA, PA.

Between 2021 and 2024, Dr. ASLANIDIS had an overall industry promotional and research financial footprint of $648 as recorded in the federal CMS Open Payments database.

$648 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ASLANIDIS's primary funding source is REGENERON HEALTHCARE SOLUTIONS, which accounts for $242 (representing 37.3% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

REGENERON HEALTHCARE SOLUTIONS

Rank 1

$242

37.3%

INTEGRA LIFESCIENCES CORPORATION

Rank 2

$173

26.7%

GENZYME CORPORATION

Rank 3

$104

16%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.